Ucb UCB.BE | BRUSSELS Exch | Medical-Diversified | MktCap €39.76B Sales €6.85B | Shares 195M Float 99M | EPS Due in 155 Days (e)

3225599999
EPS Rank 76

ucb.com

Brussels, BELGIUM Inc 1925

MGMT owns --

UCB SA engages in the research and development of biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. MORE

ANNUAL - DEC END	2016	2017	2018	2019	2020	2021	2022	2023	2024
EPS EUR	2.88	3.99	4.20	4.23	3.87	5.60	2.20	1.81	5.61
CASH FLOW/SHR EUR	1.85	4.64	5.44	4.40	5.20	7.67	5.36	3.16	5.56
PRETAX MARGIN %	18%	22%	22%	20%	16%	21%	9%	8%	19%
RETURN ON EQUITY %	10%	13%	13%	12%	10%	14%	5%	4%	11%
SALES % CHANGE	7%	9%	2%	6%	9%	8%	-5%	-5%	17%
SALES (MIL) EUR	4,147	4,530	4,632	4,913	5,347	5,777	5,517	5,252	6,152
WEEKLY	**Aug 1**	**Aug 8**	**Aug 15**	**Aug 22**	**Aug 29**	**Sep 5**	**Sep 12**	**Sep 19**	**Sep 23**
DATAGRAPH RATING	66	64	69	68	70	71	71	72	71
AVG DAILY VOL (000)	227	211	203	203	197	188	188	192	191
UP DOWN VOLUME	1.8	1.5	1.4	1.5	1.7	1.6	1.6	1.1	1.1
ACCUM/DIST RATING	34	33	31	36	29	38	29	24	24
RELATIVE STRENGTH	63	64	80	78	82	89	90	85	83
GROUP RANK	30	29	23	22	19	18	13	11	4

2025 Estimate	2026 Estimate
7.25 29%	9.96 37%
Earnings Growth Rate	**Sales Growth Rate**
2023-25 25% (69 Stability)	5%
2021-25 -7% (65 Stability)	3%
COMP RATING 95	SMR RATING A
INV T/O 1.7x 38	

DEBT %	2022-24	29%	33%	30%
TAX RATE	2022-24	18%	22%	8%
BACKLOG	2022-24	--	--	--
R & D	28.90%	BK VAL 3.91x '24		
DIV EUR	0.97 (0.5%)	DIV GR RT +2% (0)		
BETA	1.56(45.00)	ALPHA 0.03 (0.02)		
2024 EMPLOYEES 9,378 (3%)				

Exclusive Long Idea

Developed Long +7.32% in 7.7 WKS

OH -4% LOG (Fixed) PRICE

The stock broke out of a stage-one consolidation base with a with a pivot of €198.95. Support is at its rising 21-DMA (€202.77)

Strong Up/Down Volume ratio, Acc/Dist Rating, and Group Rank

Strong Composite Rating of 95 and SMR Rating of A. Double-digit EPS growth estimates for 2025 and 2026

RS line is trending upward, with good money flows

114.45 107.40 74.32 84.20 66.62 88.80 77.20 85.70 65.40 198.95 129.35

204.40 EUR +1.10 +0.54%

83 B

LOG VOLUME 3M 2M 900K -44% 215.1K

FINANCIALS	Dec 20	Mar 21	Jun 21	Sep 21	Dec 21	Mar 22	Jun 22	Sep 22	Dec 22	Mar 23	Jun 23	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25
EPS (EUR)	1.95		3.02		2.58		2.10		0.10		1.64		0.17		1.10		4.51		2.50	
EPS % CHANGE	-3%		+57%		+32%		-30%		-96%		-22%		+70%		-33%		+2,553%		+127%	
SALES (MIL EUR)	2,739.0		2,778.0		2,999.0		2,925.0		2,592.0		2,589.0		2,663.0		2,791.0		3,361.0		3,487.0	
SALES % CHANGE	+6%		+7%		+9%		+5%		-14%		-11%		+3%		+8%		+26%		+25%	
MARGIN AFTER TAX	+13.5%		+20.6%		+16.2%		+13.6%		+0.7%		+12.0%		+1.2%		+7.5%		+25.5%		+13.6%	
P/E LOW-HIGH	22-26	17-20	15-18	17-19	17-19	16-22	16-25	19-25	32-36	37-43	44-51	43-48	36-46	51-75	89-111	40-49	29-34	25-32	18-25	
FUNDS	1,397	1,369	1,379	1,392	1,392	1,471	1,581	1,413	1,401	1,387	1,385	1,430	1,464	1,472	1,590	1,697	1,828	1,825	1,825	

P/E	29
2025 Est.:	28.2
2026 Est.:	20.5
5-yr High:	111
5-yr Low:	15
vs Ind. Avg:	1.2x